US2011218325A1PendingUtilityA1

Inhibitor of Endogenous Human Interferon-Gamma

Assignee: IVANOV IVANPriority: Mar 21, 2005Filed: Feb 28, 2011Published: Sep 8, 2011

Est. expiryMar 21, 2025(expired)· nominal 20-yr term from priority

Inventors:Ivan Ivanov Rumen Tsaney Genoveva Nacheva Hans-Guenther Grigoleit Rolf Gunther

A61P 37/00C07K 14/57C07K 14/56A61K 38/00A61P 25/00C07K 2319/00

PatentIndex Score

Cited by

References

Claims

Abstract

Inactivated protein derivatives of the hIFN-γ that preserve affinity to the hIFN-γ receptor are useful in the treatment of autoimmune diseases, especially multiple sclerosis.

Claims

exact text as granted — not AI-modified

1 - 7 . (canceled) 
     
     
         8 . An inhibitor of endogenous human interferon-γ (hIFN-γ) comprising an inactivated recombinant hIFN-γ protein having binding affinity for the hIFN-γ receptor and consisting of recombinant protein hIFN-γ inactivated by UV radiation. 
     
     
         9 . An inhibitor of endogenous human interferon-γ (hIFN-γ) consisting of recombinant hIFN-γ protein, inactivated by UV radiation, with preserved binding affinity for the hIFN-γ receptor. 
     
     
         10 . An inhibitor of endogenous human interferon-γ (hIFN-γ) consisting of inactivated recombinant hIFN-γ protein having preserved binding affinity for the hIFN-γ receptor, wherein inactivation is effected by UV radiation.

Join the waitlist — get patent alerts

Track US2011218325A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.